In line with these molecular alterations, CD166− cells treated with TGFβ1 acquired a relative resistance to erlotinib (Fig. 3c) and cancer stem cell-like phenotype, including the ability of sphere formation (Fig. 3d) and CD133 expression (Fig. 3e). The gene discussed is PROM1; the disease is cancer.